Search results
Is Eli Lilly the Best Pharmaceutical Stock for You?
Motley Fool via Yahoo Finance· 2 days agoAs for the current products, they both are essentially the same drug: tirzepatide. But regulators approved the compound under the name Mounjaro in 2022...
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
The Motley Fool via AOL· 5 days agoOdds are that if you hear the word "Ozempic," you likely associate that with weight loss. It's hard not to given all the posts on social media about users losing weight thanks to the
Abbott secures FDA clearance for two over-the-counter glucose monitors
Reuters· 3 days ago, opens new tab said on Monday the U.S. health regulator had cleared the company's two new over-the-counter glucose monitoring devices, expanding its presence in a fast-growing ...
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
The Motley Fool via AOL· 5 days agoRight now, it can probably afford to run confirmatory clinical trials or even gather more data from new trials to allay concerns that regulators may have during the approval ...
Why Is Biomea Fusion (BMEA) Stock Down 63% Today?
InvestorPlace· 6 days agoBiomea Fusion (NASDAQ:BMEA) stock is falling hard on Friday after announcing a clinical hold has been put on its Phase I/II clinical trials of BMF-219....
Is Eli Lilly the Best Pharmaceutical Stock for You?
The Motley Fool via AOL· 2 days agoAs for the current products, they both are essentially the same drug: tirzepatide. But regulators approved the compound under the name Mounjaro in 2022...
Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters via Yahoo News· 4 days agoEvidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart...
Argus ups Novo Nordisk shares target on strong pipeline and growth outlook By Investing.com
Investing.com· 3 days agoThe Denmark-based company, recognized for its expansive portfolio in diabetes and obesity...
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance? | The Motley Fool
The Motley Fool· 7 days agoEli Lilly (LLY 1.52%) shares have soared more than 87% over the past year, making this player look...
Focus: Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters· 4 days ago, opens new tab Zepbound can cut heart disease risk, treat sleep apnea and address other health...